GlassScriptPhysician profile
Mary A Dameron
NPI 1467426254
$8,506.29
in general payments reported to CMS, 2019-2025
37 companies · $1,635 in 2025
The $1,635 reported for 2025 was more than what 89% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,113 · 2022: $1,661 · 2023: $2,700 · 2024: $1,397 · 2025: $1,635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,732.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,732.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,481.02 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $556.32 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $525.17 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $508.10 | 2022-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $476.42 | 2024-2025 | Auvelity, Sunosi |
| Alkermes, INC. | $476.12 | 2021-2024 | Aristada, Lybalvi |
| Corium, LLC | $430.64 | 2022-2023 | Azstarys |
| Amgen INC. | $319.45 | 2024-2025 | Repatha, Repatha, Krystexxa |
| Supernus Pharmaceuticals, INC. | $315.55 | 2021-2025 | Qelbree, Qelbree |
| Boehringer Ingelheim Pharmaceuticals, INC. | $302.33 | 2021-2023 | |
| Idorsia Pharmaceuticals US INC | $269.60 | 2023 | Quviviq |
| Glaxosmithkline, LLC. | $240.28 | 2021-2023 | Arexvy |
| Janssen Pharmaceuticals, INC | $228.77 | 2021-2022 | |
| Dexcom, INC. | $212.04 | 2023-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| E.R. Squibb & Sons, L.L.C. | $210.00 | 2021-2025 | Cobenfy |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $207.63 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $194.74 | 2024-2025 | Voquezna |
| Coloplast Corp | $189.11 | 2023-2025 | Titan |
| Novo Nordisk INC | $184.69 | 2021 | |
| Daiichi Sankyo INC. | $107.91 | 2025 | Injectafer |
| Ironshore Pharmaceuticals INC. | $102.90 | 2022-2023 | Jornay Pm |
| Medtronic, INC. | $101.00 | 2021 | |
| Lundbeck LLC | $94.92 | 2022-2024 | Rexulti |
| Biogen, INC. | $85.92 | 2023-2024 | |
| Emd Serono, INC. | $80.31 | 2024 | |
| Sage Therapeutics, LLC | $79.73 | 2025 | |
| Vanda Pharmaceuticals INC. | $76.32 | 2024 | Fanapt |
| Sanofi Pasteur INC. | $75.68 | 2023 | |
| Alexion Pharmaceuticals, INC. | $75.53 | 2024 | |
| Gilead Sciences, INC. | $69.80 | 2021 | |
| Boston Scientific Corporation | $64.62 | 2022 | |
| Tris Pharma INC | $49.64 | 2024-2025 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $42.47 | 2022-2023 | Trintellix |
| Indivior INC. | $23.16 | 2022 | |
| Avion Pharmaceuticals | $18.16 | 2023 | Methylphenidate Hydrochloride |
| Sunovion Pharmaceuticals INC. | $18.04 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $12.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Dameron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.